Camurus Ab (CAMRF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Camurus Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.094 -- 00:00:06.182 Thank you Einar and hello everyone. Welcome to our fourth quarter earnings 00:00:06.182 -- 00:00:08.866 call and full year. As 00:00:08.866 -- 00:00:13.152 customary, please note our forward-looking statements, which I will assume that you have 00:00:13.152 -- 00:00:15.075 read. 00:00:15.075 -- 00:00:19.962 So moving over to the agenda, we will begin today's call with an introduction 00:00:19.962 -- 00:00:25.570 and business highlights, followed by financial, commercial and R&D pipeline reviews, 00:00:25.570 -- 00:00:29.815 before finishing off with the key takeaways and Q&A. 00:00:29.815 -- 00:00:35.302 With me in the call today is Anders Wadsholt, Chief Financial Officer, and Richard Jameson, 00:00:35.302 -- 00:00:38.003 Chief Commercial Officer. 00:00:38.065 -- 00:00:43.552 So a quick overview of CAMERAS. We are a rapidly growing commercial stage biopharmaceutical 00:00:43.552 -- 00:00:48.558 company, focused on developing and delivering innovative long-acting treatments for people 00:00:48.558 -- 00:00:51.802 living with serious and chronic illnesses. 00:00:51.802 -- 00:00:56.508 We have become a global leader in opioid dependence therapy with our products Buvidal 00:00:56.508 -- 00:01:01.577 and Brixadi. Our commercial reach covers Europe and Australia, and we are now 00:01:01.577 -- 00:01:07.401 expanding into the US as we gear up for upcoming product launches. 00:01:07.624 -- 00:01:11.950 At the core of our offerings is the fluid crystal technology, which supports advanced 00:01:11.950 -- 00:01:17.316 long acting injectable treatments and has proven successful through both our commercial 00:01:17.316 -- 00:01:20.398 and clinical results and collaborations. 00:01:20.841 -- 00:01:26.215 Alongside our meaningful investments in ...